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The prevalent use of African traditional medicine (ATM) by 
the general public in South Africa (SA) has been reported.[1] 
It has been documented that most people consult a traditional 
health practitioner before a primary health practitioner,[2] and 
may not disclose this fact during consultation with a healthcare 
provider. [3] As a result of commercialisation and marketing, some 
herbal medicines (HMs) are readily available over the counter, 
most of them being punted as immune boosters. The use of these 
commercial herbal medicines (CHMs) with modern packaging 
and marketing practices is said to be widespread in SA.[4] The 
National Department of Health in SA has made progress towards 
institutionalisation and regulation of traditional medicine,[5] but 
there are as yet no regulations that govern the labelling and 
packaging of CHMs used as ATM.
Since these herbal mixtures have not been tested and validated, the 
effect of their presence on laboratory diagnostic tests is unknown. 
During the 2010 FIFA World Cup hosted in SA, a concern was 
raised that the use of ATMs extracted from local plants may have 
granted unfair advantage to soccer players who used them, as they 
may contain undetectable amounts of stimulants.[6] The officials 
were concerned that some herbal materials used may have produced 
compounds undetectable by the laboratory tests available at the time, 
while other products of the medicinal plants used may not have been 
included in the list of banned substances of the World Anti-Doping 
Agency (WADA). The only plants or plant-related compounds on 
the official list of WADA are cannabis, cocaine and ephedra, and they 
are listed as stimulants.[6,7] There are no listed compounds related to 
ATM.
However, there could be more issues concerning the use of 
HMs by sportspeople. The HMs may have properties similar to 
some banned substances, so that when tested, a sportsperson 
could unknowingly test positive for banned substances. Common 
substances known to cause false-positive results on urine screening 
tests for drugs of abuse (DoA) include the Vicks inhaler testing 
positive for amphetamine, non-steroidal anti-inflammatory drugs 
such as ibuprofen testing positive for barbiturates, and cannabinoids 
and some fluoroquinolones testing positive for opiates.[8,9] Ma 
huang, a Chinese HM, caused a false-positive screening test for 
amphetamines, which was confirmed to be a cross-reaction of the 
ephedrine in the product.[10]
Another area of concern is adulteration of samples. Adulteration 
is a process of deliberate interference with the process of specimen 
collection, transport or analysis, with the intention of avoiding 
a positive test outcome. In vivo adulteration is the intake of 
interfering substances such as drugs, or lots of water, before 
sample collection. In vitro adulteration is when substances are 
added into the urine sample after collection to alter the results, 
mainly to cause a false negative. Substances commonly used for 
adulteration include drug-free human, animal or synthetic urine 
or assay interferants.[11,12]
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Background. The prevalent use of African traditional medicine by the general public has been reported. With commercialisation and 
marketing, some of the herbal medicines (HMs) used are readily available over the counter, most of them promoted as immune boosters. 
These commercial HMs have not been taken through clinical trials and other tests that would validate their composition and safety, and 
other properties such as their effect on laboratory diagnostic tests.
Objective. To investigate the cross-reactivity of selected HMs with commonly tested drugs of abuse (DoA) using a qualitative rapid 
urinalysis assay.
Methods. The six HMs selected were bought from local pharmacies. A rapid urinalysis screening test was performed with the Instant View 
Multi-Drug of Abuse Test kit from Labstix Diagnostics. Drug-free urine (DFU) was pooled from samples donated by healthy volunteers. 
Urine samples that had tested positive for DoA were obtained from a pharmacology laboratory. Aliquots of the urine samples were spiked 
with the HMs in neat and diluted form, and tested at various time intervals.
Results. The results for the DFU samples spiked with the HMs remained negative. There were no significant changes in pH or specific 
gravity of the samples. The results of samples that had tested positive for tetrahydrocannabinol (THC) were not altered by five of the HMs 
when spiked at 40% v/v. The HM Ngoma Herbal Tonic Immune Booster caused false-negative results for the THC test.
Conclusion. An important finding is that the herbal mixture Ngoma Herbal Tonic Immune Booster caused false-negative results for the 
cannabinoid screening test. It adds to the list of substances that may be potential adulterants of urine for screening tests.
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Generally, urine is tested routinely for DoA in health facilities to aid 
the diagnosis of potential abusers and some psychiatry patients on 
admission. The other important testing is for banned substances in 
special populations such as those whose work environment requires 
that they be drug free, and people involved in professional sport. 
Qualitative screening tests are initially used to test for the presence 
of the DoA, as they are quick, sensitive, relatively economical and 
simple to use.[8,11] Results of screening assays are used to indicate 
whether further testing is required (as illustrated in Fig. 1) and 
provide a guide for follow-up action from a clinical perspective.
A rapid urinalysis assay based on an immunoassay method 
is the screening test commonly used for DoA. It is based on the 
principle of antigen-antibody reaction in which the drug or drug 
metabolite present in urine will interact with a labelled polyclonal or 
monoclonal antibody provided.[13,14] Various substances may interfere 
with immunoassays by cross-reacting with the test reagents and 
resulting in false-negative, false-positive or invalid results.
Objective
Literature searches provided no results for cross-reactivity of ATMs, 
or the influence of ATMs on laboratory tests. This study therefore 
sought to establish whether any of the commonly used CHMs may 
affect the outcomes of a rapid qualitative screening test for DoA. It 
was intended to show whether the presence of the CHMs would alter 
the results of a rapid urinalysis assay.
Methods
Permission for the study (ref. no. MREC/M/09/2011:PG) was granted 
by the Sefako Makgatho Health Sciences University (SMU) Research 
Committee and the Superintendent of Dr George Mukhari Academic 
Hospital.
The rapid urinalysis assay
The test kit used was the Instant View Multi-Drug of Abuse Test 
kit from Labstix Diagnostics (SA). It consists of test cassettes, each 
with six panels for concurrent testing of amphetamine, cocaine, 
methamphetamine, morphine, tetra-hydrocannabinol (THC) and 
methylenedioxymethamphetamine. The test is a one-step lateral flow 
chromatographic immunoassay. Each panel contains drug-protein 
conjugate immobilised on a porous membrane support. The test is 
based on the principle of competition for limited binding sites on the 
antibody between the drug or drug metabolite present in the urine 
sample and the immobilised drug-protein conjugate. If the drug is 
absent in the urine, or is present in below cut-off levels, a coloured 
conjugate will interact with the drug antigen immobilised in the test 
line and form a coloured line. If the drug or metabolite is present, 
it will bind to and saturate all the binding sites on the antibody 
conjugate, preventing any binding by the drug antigen at the test 
area. The results are negative if two colour lines appear, one in the 
test area and the other in the control area, regardless of the intensity 
of the line. The results are positive when only one colour line appears 
in the control site and are invalid if no colour line appears on the test 
as well as the control site.
A 10-test dipstick kit from Labstix Diagnostics was used to test 
qualitatively for pH and specific gravity (SG).
The herbal mixtures and preparation
The six CHMs selected for the study are used as immune boosters or 
to strengthen the body and are commonly sold in many retail outlets; 
they were bought from local pharmacies. They were Intlamba Zifo 
(denoted HM1 for the purposes of this study), Maphilisa HM 
(HM2), Matla African Medicine for All Diseases (HM3), Ngoma 
Herbal Tonic Immune Booster (HM4), Stametta Body Healing 
Liquid (HM5) and Vuka Uphile Immune Booster (HM6). From each 
of the six CHMs, three serial dilutions of 10, 100 and 1 000 times 
were made with distilled water. These HMs were taken through the 
test procedure outlined in Fig. 2.
Testing drug-free urine (DFU)
Ten urine samples were collected from healthy volunteers, each of 
whom confirmed that they had not taken any drugs, HMs or over-
the-counter medicines within the preceding 7 days. The samples were 
pooled as DFU. Both the individual samples and the DFU were tested 
with the dipsticks for pH and SG. The remaining pooled DFU was 
stored in the refrigerator at 4°C.
Four samples of 9 mL each of DFU were made for each of the 
six CHMs. A volume of 1 mL each of the neat HM and the three 
dilutions were added to the samples. A dipstick test was done on each 
spiked DFU sample and the results were recorded. The spiked DFU 
samples were then tested using the Instant View Multi-Drug of Abuse 
Test cassette, following the instructions in the test kit manual. The 
test was repeated at time intervals of 8, 24, 48, 72, 96 and 120 hours 
and the results were recorded. Following up on the results of the test, 
six aliquots of the DFU were each spiked with the HMs at 40% v/v 
(2 400 µL DFU + 1 600 µL CHM). The control for each sample was 
composed of 2 400 µL DFU plus 1 600 µL of distilled water to make 
up for the dilution.
Fig. 1. Flow diagram for routine urine testing for drugs of abuse. (HPLC = 
high-performance liquid chromatography; GC-MS = gas chromatography-
mass spectrometry).
Urine sample
Qualitative rapid test 
(immunoassay)
Positive results Negative results
Quantitative conrmation test 
(e.g. immunoassay method, 
HPLC, GC-MS methods)
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Report results with actual 
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Qualitative rapid urine screening test 




Urine testing negative 
for DoA (DFU)
Spiked with HMs at
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Fig. 2. Outline of the method used. (DoA = drugs of abuse; DFU = drug-free 
urine; D-U = positive urine samples; HMs = herbal medicines.)
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Testing urine positive for DoA
Urine samples that had been sent to SMU’s Department of 
Pharmacology and Therapeutics laboratory for routine testing and 
had tested positive for any of the tested substances were collected. 
The positive urine samples (D-U) were labelled accordingly, and 
centrifuged for 5 minutes at 1 000 rpm (250 g). Each supernatant was 
collected and stored in the refrigerator at 4°C until needed.
Six aliquots of the D-U samples were each spiked with one of 
the six HMs at 40% v/v. The positive control for each sample was 
composed of 2 400 µL D-U plus 1 600 µL DFU. These samples 




The urine samples obtained from healthy volunteers appeared 
normal. The colour of the samples was various shades of amber, but 
none of the observed parameters deviated from the normal ranges 
as indicated by the dipstick test. The pH and SG of the individual 
urine samples differed, but the pooled sample values were pH 6.0 
and SG 1.020.
The results of the rapid qualitative test on the spiked DFU samples 
were all negative for the tested DoA and remained negative from 
day 1 till day 5. The dipstick results for pH and SG also remained the 
same for each of the samples throughout the 5 days of testing.
The results for the 40% v/v spiked urine samples were also negative, 
and remained negative throughout the 5 days. The mean SG and pH 
for the DFU spiked with the HMs were 1.020 and 5.5, respectively.
Testing urine that was positive for DoA
Eight urine samples (D-U) that had tested positive for THC were 
used in this assay. The pH of samples ranged from 5 to 7.5 and the 
SG from 1.005 to 1.030. The pH of the controls was between 5 and 
6.5 and the SG between 1.010 and 1.030. The controls for all the 
D-U samples remained positive for THC. The results of seven D-U 
samples spiked with HM1, HM2, HM3, HM5 and HM6 remained 
positive for THC in all concentrations of the HMs tested, from the 
lowest to the highest (40% v/v).
The D-U samples spiked with HM4 at the highest concentration 
(40% v/v) tested negative for THC. Because this HM was the only one 
that was alcohol based, alcohol had to be excluded as a possible cause 
of the false-negative result. A 13.5% methanol solution was used to 
spike some D-U samples, which were then taken through the same 
procedure. The results of the spiked D-U samples remained positive, 
confirming that alcohol did not alter the results.
Discussion
Five of the six HMs tested had no influence on the quantitative 
rapid urinalysis assay. HM4, Ngoma Herbal Tonic Immune Booster, 
showed false-negative results for THC in the urine samples that 
were positive for THC when spiked at 40% v/v with HM4. It is 
stated on the container of this HM that it contains Sutherlandia, 
Echinacea, dandelion, alfalfa (lucerne), Aloe ferox, Harpagophytum 
(devil’s claw) and alcohol (13.5%). Alcohol was excluded as a 
possible cause of the false-negative result. The plausible explanation 
for the false-negative result could therefore be that alcohol as a 
solvent extracted some lipophilic compounds from the plants 
used, which would not be extracted by water as a solvent. These 
compounds would have then interfered with the test reagents, 
resulting in the false-negative results.
For the test to be positive, the drug metabolites in the urine 
sample compete for binding on the immobilised protein conjugate 
(antibody) with the colour-coded drug antigen on the test panel. 
A negative test result occurs when the colour-coded drug antigen 
binds to the antibody. The compounds in HM4 interacted with the 
test reagents and the THC in the sample in such a way that the drug 
metabolite could not bind to the antibody.
There are several ways in which false-negative results could occur 
for a particular drug when using immunoassays. A false negative 
may occur when the drug is present in the sample but the detection 
limit of the method is too high, or when the actual concentration 
of the drug in the sample is very low.[8,13] Most screening tests have 
cut-off concentrations above which the results would be reported 
as positive. [8,14-16] It may also be caused by cross-reactivity of the 
antibody in the assay, the time lapse between drug ingestion and 
specimen collection, or adulteration of the sample.[15] 
For HM4, the false-negative results occurred at high concentration 
(40% v/v). Although the test used is a qualitative test, it has a 
quantitative part due to the cut-off levels, which give a guide to the 
possible concentration of the substance if positive.[14] The suggestion 
here is that the presence of HM4 at low levels, which are the most 
likely in vivo physiological levels, would not affect the screening test. 
The high concentration used would be most likely to be achieved by 
in vitro sample manipulation, therefore suggesting that HM4 could be 
an adulterant for THC. Dilution of a sample, which would normally 
cause reduced concentration to below cut-off levels[11] is not a factor 
in this case because the control sample remained positive.
The false-negative results could also have been caused by cross-
reactivity of the antibody in the assay with one or more plant 
compounds present in the HM. As is well known in HMs, there could 
be undeclared ingredients in the mixture owing to either deliberate 
or unintentional contamination,[4,17] and also because manufacturers 
of commercial HMs protect their recipes, as they consider themselves 
to hold unofficial patents thereof.[18] Screening tests are designed 
to detect classes of drugs, so although they are sensitive they have 
low specificity.[11] THC is a highly lipid-soluble compound of plant 
origin. It could be that the antibody to THC in the assay has variable 
degrees of reactivity or affinity towards drugs or metabolites with 
identical chemical structure to THC, or with unrelated chemical 
structures. HM4 may contain one or more plant compounds that 
are structurally related to THC, since THC is of plant origin. 
Plant compounds that are extracted in alcohol include glycosides, 
sugars, amino acids, terpenoids, alkaloids and polyphenols.[19,20] 
Whether these were the compounds that interfered with the test is 
speculative at this stage, as there could be more compounds present. 
The result cannot be extrapolated to physiological levels, as it was 
observed at a high concentration (40% v/v) of HM4. However, the 
result permits the possibility of the risk of the use of HM4 as an 
adulterant. The cannabinoid assay was recognised to be the assay 
most susceptible to false-negative results after six out of 16 chemicals 
commonly used as adulterants reported false-negative results.[21] The 
substances interfering with cannabinoid immunoassays included 
ibuprofen, tolmetin[10] and common household chemicals such 
as drain cleaner, ammonia and bleach.[15,21] This is the first report 
of an ATM, particularly one available over the counter, being a 
potential adulterant to a cannabinoid urine screening test using a 
quantitative lateral flow chromatography immunoassay. The outcome 
also signifies the importance of appropriate labelling of CHMs, which 
may provide information on the range of possible compounds that 
may be present in a herbal mixture.
Study limitations
The sample set for this study was small, so a wider study with more 
samples and replicates and including more herbal medicinal products 
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should be done. The study method used a rapid screening test from 
only one manufacturer. The results may therefore not be generalisable 
to the test kits from other manufacturers.
Conclusion
Of the six HMs tested, only one showed the potential of interfering 
with a rapid, qualitative urine test for DoA. Ngoma Herbal Tonic 
Immune Booster caused false-negative results for THC. This is the 
first finding of the possibility of commercial HMs used as ATMs 
interfering with rapid, qualitative screening tests. The findings 
therefore facilitate the route for further studies investigating 
whether the use of these medicines interferes with diagnostic tests 
in general.
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